New hope for Hard-to-Treat leukemia: Two-Drug combo enters human trials
NCT ID NCT05091424
First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 4 times
Summary
This early-stage trial is testing two drugs, mosunetuzumab and venetoclax, in people with chronic lymphocytic leukemia (CLL) that has come back or stopped responding to treatment. Mosunetuzumab is given as a shot under the skin, and venetoclax is a daily pill. The study will check for safety, side effects, and whether the drugs help shrink the cancer. About 137 participants will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mosunetuzumab (Lunsumio) and venetoclax (Venclexta)
- What this could lead to
- If successful, this could offer a new treatment option for people with CLL that has stopped responding to other therapies.
- What could go wrong
- This is an early Phase 1 trial focused on safety, so it is too soon to know if the drugs will work. Side effects like cytokine release syndrome are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
A.O. Spedali Civili Di Brescia-P.O. Spedali Civili
RECRUITINGBrescia, Lombardy, 25123, Italy
-
Asst Grande Ospedale Metropolitano Niguarda
RECRUITINGMilan, Lombardy, 20162, Italy
-
Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia
RECRUITINGSant'Andrea Delle Fratte (PG), Umbria, 06132, Italy
-
Christie Hospital NHS Trust
RECRUITINGManchester, M20 4BX, United Kingdom
-
Chu de Clermont Ferrand
WITHDRAWNClermont-Ferrand, 63003, France
-
Churchill Hospital
RECRUITINGOxford, OX3 7LE, United Kingdom
-
Hospital Universitari Vall d'Hebron
RECRUITINGBarcelona, 08035, Spain
-
Hospital de la Santa Creu i Sant Pau
RECRUITINGBarcelona, 08025, Spain
-
Huntsman Cancer Institute at The University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
-
IUCT Oncopole
WITHDRAWNToulouse, 31059, France
-
Mayo Clinic Rochester
RECRUITINGRochester, Minnesota, 55902, United States
-
Memorial Sloan-Kettering Cancer Center
WITHDRAWNNew York, New York, 10065, United States
-
Monash Medical Centre
RECRUITINGMelbourne, Victoria, 3168, Australia
-
Osp. San Raffaele
RECRUITINGMilan, Lombardy, 20132, Italy
-
PRATIA MCM Kraków
RECRUITINGKrakow, 30-727, Poland
-
Peking University People's Hospital
RECRUITINGBeijing, 100044, China
-
Peter MacCallum Cancer Center
COMPLETEDEast Melbourne, Victoria, 3002, Australia
-
Princess Alexandra Hospital Woolloongabba
RECRUITINGWoolloongabba, Queensland, 4102, Australia
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
-
Seoul St Mary's Hospital
RECRUITINGSeoul, 06591, South Korea
-
Southern Medical University Nanfang Hospital
RECRUITINGGuangzhou, 510515, China
-
The First Affiliated Hospital of Nanchang University
RECRUITINGNanchang, China
-
The James Cancer Hospital and Solove Research Institute
RECRUITINGColumbus, Ohio, 43210, United States
-
Tianjin Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, 301600, China
-
Uni of Texas - Md Anderson Cancer Center
WITHDRAWNHouston, Texas, 77030, United States
-
Uniklinik Koln
WITHDRAWNCologne, 50937, Germany
-
Universitätsklinikum Augsburg
RECRUITINGAugsburg, 86156, Germany
-
Universitätsklinikum Ulm
WITHDRAWNUlm, 89081, Germany
-
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu
RECRUITINGWroc?aw, 50-367, Poland
-
Uniwersyteckie Centrum Kliniczne
RECRUITINGGda?sk, 80-214, Poland
-
Yeouido St. Mary's Hospital
RECRUITINGSeoul, 07345, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can a Three-Drug combo outsmart High-Risk CLL?
- Can a gentler dose of zanubrutinib keep CLL at bay in the very elderly?
- Can a Two-Drug combo wipe out hidden leukemia cells?
- Can a Chemo-Free pill combo outsmart leukemia at first diagnosis?